Skip to content

Treating Violence-related PTSD and Substance Risk in Low-income, Urban Adolescents

Treating Violence-related PTSD and Substance Risk in Low-income, Urban Adolescents

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03737383
Acronym
POWER-NET
Enrollment
124
Registered
2018-11-09
Start date
2017-12-01
Completion date
2021-08-31
Last updated
2026-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Posttraumatic Stress Disorder, Substance Use Disorders

Brief summary

This project will provide initial feasibility and efficacy data for the implementation of Narrative Exposure Therapy (NET) to urban, at-risk youth. Posttraumatic stress and substance use outcomes, as well as participant responses to the intervention, will be examined.

Detailed description

The goal of the proposed study is to gather preliminary feasibility and efficacy data for an innovative intervention (Narrative Exposure Therapy: NET) to promote adolescent mental health related to interpersonal trauma (IPT). Among those at highest risk for interpersonal violence and its sequelae are youth from urban, low-resourced neighborhoods. Post-traumatic stress disorder (PTSD) is a common outcome associated with IPT. Substance misuse (SUB) is a frequent concomitant of PTSD. NET is a promising intervention to reduce PTSD symptoms and associated psychological distress, via the supported reconstruction (narrative telling) of the traumas. NET has a critical advantage over existing PTSD treatments in that it can be delivered in a brief format, in community settings where at-risk adolescents are likely to be found. Despite its promise in treating adolescent distress, NET has yet to be tested as an intervention for those who have interpersonal trauma-related PTSD. Further NET's influence on SUB has not been examined. Accordingly, the objective of this project is to conduct a pilot study (N=30) to estimate NET treatment effects on PTSD symptoms and SUB in IPT-exposed urban adolescents (ages 16-21). Both feasibility and preliminary efficacy data will be collected to serve as pilot work for a larger-scale NIH proposal. Recruitment and intervention will be set within community partners where the adolescents already are connected and are receiving social or psychological services. Outcome data will be collected at: (T0) Baseline, and at 1(T1), and 3 months (T2) follow-up assessments. Participant responses to the intervention will be assessed post-intervention. Change in PTSD, SUB will be estimated with effect sizes and inferential tests. Preliminary evidence of efficacy and feasibility will pave the way for further NET development to offer a patient-oriented, community-based, intervention that will promote adolescent mental health for those at greatest risk for health access and outcomes disparities.

Interventions

BEHAVIORALNarrative Exposure Therapy

brief, trauma-focused treatment.

Sponsors

State University of New York at Buffalo
Lead SponsorOTHER
National Center for Advancing Translational Sciences (NCATS)
CollaboratorNIH

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
16 Years to 25 Years
Healthy volunteers
Yes

Inclusion criteria

* Adolescents (ages 16-25), * Positive PTSD diagnosis (CAPS diagnosis) * Positive lifetime incidence of interpersonal violence-related trauma.

Exclusion criteria

* Actively suicidal with an immediate referral to the community agency crisis staff * Severe cognitive delay * Active psychosis

Design outcomes

Primary

MeasureTime frameDescription
Posttraumatic Stress Disorder Checklist-Civilian VersionAt baseline, at 1 month follow up, and at 3 month follow upassessed via PTSD checklist. The minimum score for this measure is 0 while the maximum is 80. Higher scores indicate more severe PTSD symptoms.

Secondary

MeasureTime frameDescription
Alcohol Use Disorders Identification Test (AUDIT)Only 1 participant finished the follow up for 1 month and 3 month (they are a different participant).alcohol use assessed via AUDIT. The minimum score for this measure is 0 while the maximum is 40. Higher scores indicate more alcohol use.
Young Adult Alcohol Consequences Questionnaire (YAACQ)Only 1 participant finished the follow up for 1 month and 3 month (they are a different participant).alcohol consequences assessed via YAACQ. The minimum score for this measure is 0 while the maximum is 48. Higher scores indicate more alcohol consequences.

Countries

United States

Contacts

STUDY_CHAIRStephen Tiffany, Ph.D.

University at Buffalo

Participant flow

Recruitment details

We recruited 50 participants for the phase 1 survey, 40 of them finished. We then recruited 74 participants into phase 2 and 60 completed the baseline (different participants than Phase 1). 1 Participant came back for the 1 month follow up. 9 participants came back for the 3 month follow up. 1 of them completed that follow up. The population this study used (homeless teens and young adults) made it extremely difficult to maintain contact so it was hard to follow up resulting in low numbers.

Baseline characteristics

Characteristic
Age, Categorical
Baseline (Phase 1)
<=18 years
16 Participants
Age, Categorical
Baseline (Phase 1)
>=65 years
0 Participants
Age, Categorical
Baseline (Phase 1)
Between 18 and 65 years
24 Participants
Age, Categorical
Baseline (Phase 2)
<=18 years
11 Participants
Age, Categorical
Baseline (Phase 2)
>=65 years
0 Participants
Age, Categorical
Baseline (Phase 2)
Between 18 and 65 years
49 Participants
Age, Continuous
Baseline (phase 1 and phase 2)
18.95 years
STANDARD_DEVIATION 2.51
Age, Continuous
Baseline (phase 2)
19.66 years
STANDARD_DEVIATION 2.35
Race (NIH/OMB)
Baseline (Phase 1)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Baseline (Phase 1)
Asian
0 Participants
Race (NIH/OMB)
Baseline (Phase 1)
Black or African American
20 Participants
Race (NIH/OMB)
Baseline (Phase 1)
More than one race
7 Participants
Race (NIH/OMB)
Baseline (Phase 1)
Native Hawaiian or Other Pacific Islander
1 Participants
Race (NIH/OMB)
Baseline (Phase 1)
Unknown or Not Reported
3 Participants
Race (NIH/OMB)
Baseline (Phase 1)
White
9 Participants
Race (NIH/OMB)
Baseline (Phase 2)
American Indian or Alaska Native
1 Participants
Race (NIH/OMB)
Baseline (Phase 2)
Asian
0 Participants
Race (NIH/OMB)
Baseline (Phase 2)
Black or African American
33 Participants
Race (NIH/OMB)
Baseline (Phase 2)
More than one race
6 Participants
Race (NIH/OMB)
Baseline (Phase 2)
Native Hawaiian or Other Pacific Islander
1 Participants
Race (NIH/OMB)
Baseline (Phase 2)
Unknown or Not Reported
5 Participants
Race (NIH/OMB)
Baseline (Phase 2)
White
14 Participants
Region of Enrollment
United States
100 participants
Sex: Female, Male
Baseline (Phase 1)
Female
20 Participants
Sex: Female, Male
Baseline (Phase 1)
Male
20 Participants
Sex: Female, Male
Baseline (Phase 2)
Female
16 Participants
Sex: Female, Male
Baseline (Phase 2)
Male
44 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 500 / 74
other
Total, other adverse events
0 / 500 / 74
serious
Total, serious adverse events
0 / 500 / 74

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 16, 2026